Stock listing
OTC:IPSEY Ipsen SA Stock
US listing (OTC) of Ipsen SA · home listing Euronext:IPN
Follow Ipsen SA into a list and get an email when it puts out news.
Share price · OTC:IPSEY
$45.10 USD +0.85 (+1.9%)
Close on Nov 20, 2026
- Day range
- $45.10 – $45.10 USDNov 20, 2026
- Volume
- 100 sharesNov 20, 2026
- Market cap
- $14.87B USDAt the close on Nov 20, 2026 · price × 329.7M shares outstanding
- 52-week range
- $34.24 – $50.82 USDLowest and highest trades, Nov 24, 2025 – Nov 20, 2026
- Traded on an average day
- $55,883 USDMedian day 100 shares · 22 days with no trades · last 3 months, Aug 20, 2026 – Nov 6, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| Euronext:IPN · Home | €161.60 EUR | -1.40 (-0.9%) | 95,521 | €163.70 | €164.30 | €161.60 | €163.00 | Close on Nov 20, 2026 |
| OTC:IPSEY | $45.10 USD | +0.85 (+1.9%) | 100 | $45.10 | $45.10 | $45.10 | $44.25 | Close on Nov 20, 2026 |
| Frankfurt:I7G | €159.50 EUR | -3.60 (-2.2%) | — | €159.50 | €159.50 | €159.50 | €163.10 | Close on Nov 20, 2026 |
| Munich:I7G | €159.60 EUR | -4.50 (-2.7%) | — | €160.10 | €160.10 | €159.60 | €164.10 | Close on Nov 20, 2026 |
| Frankfurt:I7G0 | €39.80 EUR | -1.00 (-2.5%) | — | €39.80 | €39.80 | €39.80 | €40.80 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 6, 2026 · OTC:IPSEY · USD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $44.06 | +0.394 | +0.9% | $44.06 | $44.06 | $44.06 | 900 | |
| $43.67 | 0.00 | 0.0% | $43.67 | $43.67 | $43.67 | 0 | |
| $43.67 | -0.054 | -0.1% | $43.67 | $43.67 | $43.67 | 800 | |
| $43.72 | -0.56 | -1.3% | $43.72 | $43.72 | $43.72 | 400 | |
| $44.28 | -0.181 | -0.4% | $44.00 | $44.28 | $43.76 | 1,200 | |
| $44.46 | +0.107 | +0.2% | $43.89 | $44.46 | $43.89 | 500 | |
| $44.35 | +2.344 | +5.6% | $44.35 | $44.35 | $44.35 | 500 | |
| $42.01 | -0.479 | -1.1% | $42.01 | $42.01 | $42.01 | 9,300 | |
| $42.49 | +0.152 | +0.4% | $42.49 | $42.49 | $42.49 | 11,208 | |
| $42.34 | -1.513 | -3.5% | $42.34 | $42.34 | $42.34 | 2,803 | |
| $43.85 | +0.854 | +2.0% | $43.85 | $43.85 | $43.85 | 1,200 | |
| $43.00 | 0.00 | 0.0% | $43.00 | $43.00 | $43.00 | 0 | |
| $43.00 | +2.066 | +5.0% | $43.00 | $43.00 | $43.00 | 300 | |
| $40.93 | 0.00 | 0.0% | $40.93 | $40.93 | $40.93 | 0 | |
| $40.93 | 0.00 | 0.0% | $40.93 | $40.93 | $40.93 | 0 | |
| $40.93 | 0.00 | 0.0% | $40.93 | $40.93 | $40.93 | 0 | |
| $40.93 | +0.93 | +2.3% | $40.93 | $40.93 | $40.93 | 300 | |
| $40.00 | -0.654 | -1.6% | $40.00 | $40.00 | $40.00 | 1,100 | |
| $40.65 | 0.00 | 0.0% | $40.65 | $40.65 | $40.65 | 21 | |
| $40.65 | 0.00 | 0.0% | $40.65 | $40.65 | $40.65 | 0 | |
| $40.65 | +0.504 | +1.3% | $40.65 | $40.65 | $40.65 | 400 | |
| $40.15 | +0.26 | +0.7% | $39.12 | $40.15 | $39.12 | 16,300 | |
| $39.89 | 0.00 | 0.0% | $39.89 | $39.89 | $39.89 | 0 | |
| $39.89 | +0.14 | +0.4% | $39.83 | $39.89 | $39.83 | 1,500 | |
| $39.75 | -2.148 | -5.1% | $39.40 | $39.75 | $39.40 | 9,600 | |
| $41.90 | 0.00 | 0.0% | $41.90 | $41.90 | $41.90 | 0 | |
| $41.90 | 0.00 | 0.0% | $41.90 | $41.90 | $41.90 | 0 | |
| $41.90 | +1.008 | +2.5% | $41.90 | $41.90 | $41.90 | 200 | |
| $40.89 | 0.00 | 0.0% | $40.89 | $40.89 | $40.89 | 0 | |
| $40.89 | -1.09 | -2.6% | $40.31 | $40.89 | $40.31 | 500 | |
| $41.98 | +0.01 | 0.0% | $40.66 | $41.98 | $40.66 | 1,600 | |
| $41.97 | 0.00 | 0.0% | $41.97 | $41.97 | $41.97 | 0 | |
| $41.97 | -0.438 | -1.0% | $41.97 | $41.97 | $41.97 | 100 | |
| $42.41 | 0.00 | 0.0% | $42.41 | $42.41 | $42.41 | 28 | |
| $42.41 | -2.342 | -5.2% | $42.41 | $42.41 | $42.41 | 200 | |
| $44.75 | 0.00 | 0.0% | $44.75 | $44.75 | $44.75 | 0 | |
| $44.75 | -1.478 | -3.2% | $44.82 | $44.82 | $44.75 | 300 | |
| $46.23 | +0.308 | +0.7% | $46.23 | $46.23 | $46.23 | 400 | |
| $45.92 | 0.00 | 0.0% | $45.92 | $45.92 | $45.92 | 0 | |
| $45.92 | -0.58 | -1.2% | $45.92 | $45.92 | $45.92 | 200 | |
| $46.50 | 0.00 | 0.0% | $46.50 | $46.50 | $46.50 | 0 | |
| $46.50 | 0.00 | 0.0% | $46.50 | $46.50 | $46.50 | 0 | |
| $46.50 | +0.59 | +1.3% | $46.50 | $46.50 | $46.50 | 200 | |
| $45.91 | -3.24 | -6.6% | $45.91 | $45.91 | $45.91 | 10,300 | |
| $49.15 | 0.00 | 0.0% | $49.15 | $49.15 | $49.15 | 0 | |
| $49.15 | 0.00 | 0.0% | $49.15 | $49.15 | $49.15 | 100 | |
| $49.15 | 0.00 | 0.0% | $49.15 | $49.15 | $49.15 | 0 | |
| $49.15 | 0.00 | 0.0% | $49.15 | $49.15 | $49.15 | 0 | |
| $49.15 | 0.00 | 0.0% | $49.15 | $49.15 | $49.15 | 100 | |
| $49.15 | 0.00 | 0.0% | $49.15 | $49.15 | $49.15 | 100 | |
| $49.15 | +1.55 | +3.3% | $49.15 | $49.15 | $49.15 | 100 | |
| $47.60 | 0.00 | 0.0% | $47.60 | $47.60 | $47.60 | 0 | |
| $47.60 | 0.00 | 0.0% | $47.60 | $47.60 | $47.60 | 0 | |
| $47.60 | 0.00 | 0.0% | $47.60 | $47.60 | $47.60 | 0 | |
| $47.60 | 0.00 | 0.0% | $47.60 | $47.60 | $47.60 | 0 | |
| $47.60 | +0.035 | +0.1% | $47.60 | $47.60 | $47.60 | 1,400 |
- Ticker
- OTC:IPSEY
- Asset type
- Stock
- Sector
- Health care
- Industry
- Pharmaceuticals
- Exchange
- OTC
- Currency
- USD
What changed lately
Latest news release · Nov 6, 2026
Ipsen - October 2026 - Monthly information relative to the total number of voting rights and shares composing the share capital
Latest earnings call · Jul 30, 2026
Ipsen (Euronext:IPN) Q2 2026 Earnings Call
Replay and transcript
Latest deck · Oct 22, 2026
Q3 2026 Earnings Presentation
Earnings · 20 slides
Latest news
Ipsen - October 2026 - Monthly information relative to the total number of voting rights and shares composing the share capital
Nov 6, 2026
Closed $44.06 (+0.9%) on Nov 6, 2026
IQIRVO® late-breaking data raises ambitions in PBC with more than 85% of patients on treatment achieving ALP normalization
Nov 5, 2026
Closed $43.67 (0.0%) on Nov 5, 2026
Ipsen delivers outstanding sales growth in the first nine months of 2026 and further upgrades its full-year guidance
Oct 22, 2026
Closed $43.00 (0.0%) on Oct 22, 2026
IPSEN - Buy-back programme - Art 5 of MAR - Week 39 - 2026
Sep 28, 2026
Closed $40.89 (-2.6%) on Sep 28, 2026
IPSEN - Achats effectués dans les conditions de l'Article 5 du Règlement MAR - Semaine 39 - 2026
Sep 28, 2026
Closed $40.89 (-2.6%) on Sep 28, 2026
IPSEN - Buy-back programme - Art 5 of MAR - Week 38 - 2026
Sep 22, 2026
Closed $42.41 (0.0%) on Sep 22, 2026
IPSEN - Achats effectués dans les conditions de l'Article 5 du Règlement MAR - Semaine 38 - 2026
Sep 21, 2026
Closed $42.41 (0.0%) on Sep 22, 2026
Ipsen appoints Mariette Finet to its Board of Directors
Sep 18, 2026
Closed $44.75 (0.0%) on Sep 18, 2026
Ipsen nomme Mariette Finet administratrice au sein de son Conseil d’administration
Sep 17, 2026
Closed $44.75 (0.0%) on Sep 18, 2026
Correction: IPSEN - Buy-back programme - Art 5 of MAR - Week 36- 2026
Sep 15, 2026
Closed $45.92 (0.0%) on Sep 15, 2026
Ipsen SA on 6ix
- Sector
- Health care
- Industry
- Pharmaceuticals
- News releases
- 93 in the last 12 months · 138 in all · newest Nov 6, 2026 · oldest 2025
- Calls
- 7 calls with a replay · 7 with a transcript · latest Jul 30, 2026
- Decks
- 136 decks · latest Oct 22, 2026
Where Ipsen SA is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| Euronext:IPN · Home listing | Euronext | France | EUR |
| LSIN:0MH6 | LSIN | United Kingdom | EUR |
| OTC:IPSEY · This page | OTC | United States | USD |
| gettex:I7G | gettex | Germany | EUR |
| Tradegate:I7G | Tradegate | Germany | EUR |
| LS Exchange:A0ESMG | LS Exchange | Germany | EUR |
| Aquis:IPNP | Aquis | United Kingdom | EUR |
| Lang & Schwarz:A0ESMG | Lang & Schwarz | Germany | EUR |
| Aquis:IPNP | Aquis | United Kingdom | EUR |
| Dusseldorf:I7G | Dusseldorf | Germany | EUR |
| OTC:IPSEF | OTC | United States | USD |
| Frankfurt:I7G | Frankfurt | Germany | EUR |
| Hamburg:I7G | Hamburg | Germany | EUR |
| Stuttgart:I7G | Stuttgart | Germany | EUR |
| Munich:I7G | Munich | Germany | EUR |
| BIVA:IPNN | BIVA | Mexico | MXN |
| BMV:IPNN | BMV | Mexico | MXN |
| BX Swiss:IPN | BX Swiss | Switzerland | CHF |
| Dusseldorf:I7G0 | Dusseldorf | Germany | EUR |
| Frankfurt:I7G0 | Frankfurt | Germany | EUR |
| Lang & Schwarz:A1J2CW | Lang & Schwarz | Germany | EUR |
| LS Exchange:A1J2CW | LS Exchange | Germany | EUR |
| Stuttgart:I7G0 | Stuttgart | Germany | EUR |
| Turquoise:IPNP | Turquoise | United Kingdom | EUR |
| VIE:IPN | Vienna | Austria | EUR |
Valuation
P/E 30.0× against a median of 49.1×: 3rd lowest of 10 Pharmaceuticals companies shown. Statements: Year to Dec 31, 2025 · balance Jun 30, 2026 · price Nov 20, 2026
- Enterprise value
- €12.31B EUR
- P/E
- 30.0×
- EV/sales
- 3.4×
- EV/EBITDA
- 11.2×
- Price/book
- 2.8×
- Gross margin
- 70.6%
- Operating margin
- 20.3%
- Net margin
- 12.1%
- Debt to equity
- 0.2×
- Beta
- No index for this market yet
Pharmaceuticals: the 10 companies nearest in size, of 492 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| Ipsen SA · EURONEXT:IPN | US$14.62B | US$13.51B | 30.0× | 3.4× | 11.2× | 2.8× | 12.1% | 0.2× | n/a |
| Innovent Biologics, Inc. · HKEX:1801 | US$17.82B | US$15.17B | 146× | 7.8× | 75.7× | 5.7× | 6.2% | 0.1× | n/a |
| Yunnan Baiyao Group Co. Ltd. Class A · SZSE:000538 | US$15.10B | US$13.13B | 19.4× | 2.0× | n/a | 2.5× | 12.2% | 0.0× | n/a |
| Jazz Pharmaceuticals plc · NASDAQ:JAZZ | US$14.95B | US$18.48B | 72.6× | 3.9× | n/a | 3.6× | 4.4% | 1.3× | 0.64 |
| Laurus Labs Ltd. · NSE:LAURUSLABS | US$13.38B | US$13.66B | 92.5× | 16.2× | 53.2× | 20.5× | 17.1% | 0.4× | n/a |
| Zydus Lifesciences Limited · NSE:ZYDUSLIFE | US$12.92B | US$13.86B | 28.6× | 4.2× | 17.9× | 4.3× | 13.8% | 0.5× | n/a |
| Elanco Animal Health Incorporated · NYSE:ELAN | US$12.87B | US$15.85B | n/a | 3.1× | 13.1× | 1.9× | −2.9% | 0.5× | 1.20 |
| Dr. Reddy's Laboratories Ltd. · NSE:DRREDDY | US$12.50B | US$12.46B | 41.4× | 3.5× | 22.6× | 3.0× | 8.5% | 0.2× | n/a |
| Cipla Ltd · NSE:CIPLA | US$12.34B | US$11.27B | 39.5× | 3.7× | 21.6× | 3.2× | 10.4% | 0.0× | n/a |
| Mankind Pharma Ltd. · NSE:MANKIND | US$11.88B | US$12.18B | 49.1× | 7.3× | 27.7× | 6.3× | 14.6% | 0.3× | n/a |
| Zhangzhou Pientzehuang Pharmaceutical Co., Ltd. Class A · SSE:600436 | US$11.64B | US$11.32B | 58.9× | 9.5× | n/a | 5.5× | 16.7% | 0.0× | n/a |
| Median of the others | US$12.89B | US$13.40B | 49.1× | 4.1× | 22.6× | 3.9× | 11.3% | 0.3× | 0.92 |
Forecasts
Analysts' consensus from EODHD, read Nov 11, 2026. Not 6ix's view and not investment advice.
- Price target
- 162.23 EUR · Analysts' mean
- EPS, year to Dec 2026
- 16.12 · 8 analysts
- Revenue, year to Dec 2026
- 4.62B · 10 analysts
Team and board
Officers
| Officer | Role |
|---|---|
| Michelle C. Werner | EVP, President of North America |
| Pierrick Lefranc | Executive Vice President |
| Régis Mulot | EVP, Chief Human Resources Officer |
Board
| Director | Role |
|---|---|
| Catherine Bradley | Independent Director |
| Mariette Finet | Director |
Events
- Next results
- Feb 11, 2027 (expected)
Calls
| Call | When | Status |
|---|---|---|
| Ipsen (Euronext:IPN) Q2 2026 Earnings Call | Thu, Jul 30, 2026 · 8:00 AM ET | Replay |
| Ipsen (Euronext:IPN) Q1 2026 Earnings Call | Thu, Apr 23, 2026 · 8:00 AM ET | Replay |
| Ipsen (Euronext:IPN) Q4 2025 Earnings Call | Thu, Feb 12, 2026 · 8:00 AM ET | Replay |
| Ipsen (Euronext:IPN) Q3 2025 Earnings Call | Fri, Oct 24, 2025 · 8:00 AM ET | Replay |
| Ipsen (Euronext:IPN) Q2 2025 Earnings Call | Thu, Jul 31, 2025 · 4:30 PM ET | Replay |
| Ipsen (Euronext:IPN) Q1 2025 Earnings Call | Wed, Apr 16, 2025 · 8:00 AM ET | Replay |
| Ipsen (Euronext:IPN) Q4 2024 Earnings Call | Thu, Feb 13, 2025 · 7:00 AM ET | Replay |
Results days
| Quarter | Results | Share move |
|---|---|---|
| Quarter to Mar 31, 2026 | Apr 23, 2026 | +1.8% |
| Q4 2025 | Feb 12, 2026 · After close | +4.8% |
| Q2 2025 | Jul 31, 2025 · After close | −0.5% |
| Q4 2024 | Feb 13, 2025 | −6.5% |
| Q2 2024 | Jul 25, 2024 | −7.0% |
| Q4 2023 | Feb 8, 2024 | +0.7% |
| Q2 2023 | Jul 27, 2023 · After close | +1.8% |
| Q4 2022 | Feb 9, 2023 · Before open | +7.1% |
| Q2 2022 | Jul 28, 2022 · Before open | +16.2% |
| Q4 2021 | Feb 11, 2022 · Before open | +6.4% |
All 12 quarters
| Quarter | Results | Share move |
|---|---|---|
| Q2 2021 | Jul 29, 2021 | +4.7% |
| Q4 2020 | Feb 11, 2021 | −1.6% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Q3 2026 Earnings Presentation | Earnings | 20 slides | Oct 22, 2026 |
| H1 2026 Earnings Presentation | Earnings | 38 slides | Jul 30, 2026 |
| Q1 2026 Earnings Presentation | Earnings | 21 slides | Apr 23, 2026 |
| FY 2025 Earnings Presentation | Earnings | 36 slides | Feb 12, 2026 |
| J.P. Morgan Healthcare Conference 2026 | Conference | 27 slides | January 2026 |
| Q3 2025 Earnings Presentation | Earnings | 22 slides | Oct 22, 2025 |
| H1 2025 Earnings Presentation | Earnings | 33 slides | Jul 31, 2025 |
| Q1 2025 Earnings Presentation | Earnings | 19 slides | Apr 16, 2025 |
| Fact Sheet (April 2025) | Fact sheet | 1 slide | April 2025 |
| FY2024 Earnings Presentation | Earnings | 35 slides | Feb 13, 2025 |
Show 50 decks
This page holds 50 of 136 decks. Open Decks
Financials
Annual, in EUR
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 3.68B | 3.57B | 3.31B | 3.16B | 3.00B | 2.69B | 2.69B | 2.35B | 2.01B | 1.67B |
| Cost of revenue | 1.08B | 618.7M | 571.2M | 527.7M | 438.6M | 490.6M | 488.0M | 454.2M | 385.6M | 351.1M |
| Gross profit | 2.59B | 2.96B | 2.74B | 2.63B | 2.31B | 2.20B | 2.20B | 1.89B | 1.63B | 1.32B |
| Research and development | 754.0M | 686.6M | 619.3M | 445.3M | 424.4M | 405.6M | 388.8M | 302.1M | 265.8M | 231.3M |
| Selling, general and administrative | 219.0M | 216.3M | 217.8M | 205.8M | 188.2M | 187.8M | 181.4M | 165.7M | 140.8M | 125.6M |
| Operating income | 746.3M | 496.7M | 816.0M | 729.9M | 824.7M | 524.8M | 701.8M | 555.3M | 400.4M | 348.2M |
| Depreciation and amortization | 356.3M | 705.9M | 296.6M | 336.5M | 237.0M | 234.7M | 161.2M | 142.6M | 97.9M | 39.1M |
| EBITDA | 1.10B | 1.20B | 1.11B | 1.07B | 1.06B | 759.5M | 863.0M | 697.9M | 498.3M | 387.3M |
| Interest expense | 36.1M | 23.8M | 19.4M | 23.8M | 23.7M | 27.1M | 30.0M | 8.40M | 9.20M | 4.60M |
| Income before tax | 578.2M | 432.2M | 756.1M | 704.4M | 789.5M | 531.1M | -34.8M | 495.2M | 372.0M | 299.9M |
| Income tax | 133.6M | 74.9M | 136.2M | 112.3M | 158.3M | -17.8M | 19.6M | 108.1M | 101.4M | 73.5M |
| Net income | 444.5M | 345.9M | 644.4M | 648.6M | 646.6M | 548.0M | -54.9M | 389.5M | 272.3M | 225.9M |
| Earnings per share, basic | 5.32 | 4.18 | 7.79 | 7.87 | 7.82 | 6,610.00 | -0.66 | 4.68 | 3.28 | 2.73 |
| Earnings per share, diluted | 4.15 | 7.73 | 7.81 | 7.76 | 6,570.00 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 1.53B | 678.1M | 528.4M | 1.17B | 814.7M | 642.5M | 353.3M | 344.5M | 228.0M | 425.5M |
| Short-term investments | 1.00M | 1.10M | 10.6M | 31.0M | 42.4M | 26.8M | 59.3M | 600.0K | 155.1M | 6.60M |
| Receivables | 932.1M | 697.2M | 631.3M | 632.5M | 564.3M | 476.2M | 588.8M | 463.0M | 437.2M | 363.5M |
| Inventory | 256.6M | 285.5M | 289.5M | 284.1M | 219.4M | 213.9M | 214.0M | 198.5M | 167.4M | 113.3M |
| Current assets | 2.82B | 2.02B | 1.90B | 2.40B | 1.95B | 1.58B | 1.35B | 1.19B | 1.02B | 1.05B |
| Property, plant and equipment | 574.6M | 581.4M | 647.5M | 646.6M | 679.3M | 474.3M | 418.6M | 379.0M | ||
| Goodwill | 633.8M | 699.5M | 663.9M | 579.9M | 623.2M | 592.8M | 632.6M | 395.6M | 389.0M | 357.2M |
| Total assets | 6.94B | 6.44B | 6.32B | 5.61B | 4.99B | 4.31B | 4.31B | 3.38B | 3.07B | 2.42B |
| Accounts payable | 854.2M | 854.8M | 771.4M | 647.1M | 594.7M | 495.2M | 508.5M | 379.8M | 319.1M | 241.5M |
| Current liabilities | 1.44B | 1.51B | 1.63B | 1.34B | 1.23B | 1.21B | 1.45B | 959.2M | 941.7M | 561.3M |
| Long-term debt | 748.2M | 287.5M | 269.7M | 667.0M | 772.2M | 542.7M | 568.2M | 297.9M | 297.5M | 297.1M |
| Total debt | 867.1M | 426.8M | 462.9M | 771.6M | 895.9M | 1.17B | 1.47B | 587.3M | 590.2M | 340.5M |
| Total liabilities | 2.60B | 2.26B | 2.50B | 2.27B | 2.25B | 2.18B | 2.55B | 1.53B | 1.54B | 1.06B |
| Shareholders' equity | 4.34B | 4.18B | 3.83B | 3.34B | 2.74B | 2.13B | 1.75B | 1.84B | 1.53B | 1.36B |
| Shares outstanding | 83.6M | 83.4M | 83.4M | 83.1M | 83.4M | 83.4M | 83.5M | 83.2M | 83.0M | 82.6M |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | 1.14B | 915.5M | 865.9M | 971.4M | 893.3M | 771.3M | 627.7M | 570.9M | 422.9M | 317.8M |
| Capital spending | -105.3M | -782.5M | -116.2M | -252.9M | -96.0M | -81.4M | -280.6M | -105.9M | -84.5M | -81.1M |
| Free cash flow | 1.03B | 133.0M | 749.7M | 718.5M | 797.3M | 689.9M | 347.1M | 465.0M | 338.4M | 236.7M |
| Cash from investing | -615.2M | -676.6M | -1.08B | -458.6M | -332.0M | -163.7M | -1.16B | -274.3M | -777.2M | -357.1M |
| Cash from financing | 298.4M | -100.0M | -452.4M | -164.2M | -421.8M | -307.5M | 550.0M | -202.2M | 135.2M | 252.0M |
| Dividends paid | -116.2M | -99.6M | -99.6M | -100.2M | -83.1M | -83.5M | -83.2M | -83.0M | -70.2M | -70.0M |
| Share buybacks | -67.7M | -36.5M | -39.5M | -11.3M | -36.7M | -36.4M | -16.8M | -10.3M | -17.5M | -17.7M |
| Change in cash | 847.4M | 138.9M | -664.7M | 348.6M | 139.5M | 300.1M | 28.1M | 101.6M | -213.2M | 208.5M |
Filings
All 11 filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| IPSEN - Achats effectués dans les conditions de l'Article 5 du Règlement MAR - Semaine 35 - 2026 | Aug 30, 2026 | Other filings | Euronext |
Cap table
Built by 6ix from Ipsen SA’s releases
- Common shares
- 82,417,038
- Fully diluted
- 82,417,038
Fully diluted
| Line | Shares |
|---|---|
| Common shares | 82,417,038 |
Share count over time
| Count | Shares |
|---|---|
| Nov 22, 2026 | 82,417,038 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Catherine Bradley | Independent Director · Since at least Jul 29, 2026 |
| Mariette Finet | Director · Since at least Sep 18, 2026 |
| Michelle C. Werner | EVP, President of North America · Since at least Mar 12, 2026 |
| Pierrick Lefranc | Executive Vice President · Since at least Jan 27, 2026 |
| Régis Mulot | EVP, Chief Human Resources Officer · Since at least Nov 5, 2026 |
Log in to ask 6ix AI your own questions about Ipsen SA.